Icon, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, has launched Flex Advantage, a next-generation Interactive Response Technology (IRT) platform that offers enhanced randomization and clinical supply management capabilities and supports the execution of adaptive trials.
Flex Advantage incorporates a host of new features that meet the demands of the most complex protocols. The features include:
Commenting on the announcement, Malcolm Burgess, Icon’s EVP, Interactive Technologies, said, “Many of our clients are embracing adaptive trial designs to optimize their drug development programs and these designs can require rapid changes in dosing and drug supply logistics. Flex Advantage not only offers a comprehensive, state of the art drug randomization and supply management system, it also fully supports the complex logistics involved in executing adaptive trial designs.”
Flex Advantage is a component of Icon’s ICONIK Informatics Hub which combines industry leading technologies with best practices to help clients to take time and cost from their development programs.